COGNITION THERAPEUTICS INC (CGTX)
About COGNITION THERAPEUTICS INC
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$23.5M
- Total assets
- $48.4M
- Market cap
- $82.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $47.8M
- Operating income
- -$47.8M
- Income tax
- $0
- Net income
- -$23.5M
- EPS (basic)
- $-0.32
- EPS (diluted)
- $-0.32
Balance sheet
- Total assets
- $48.4M
- Current assets
- $48.0M
- Total liabilities
- $14.1M
- Current liabilities
- $13.9M
- Shareholders’ equity
- $34.3M
Cash flow
- Operating cash flow
- -$24.6M
- Investing cash flow
- $9.0K
- Financing cash flow
- $36.6M
- Net cash flow
- $12.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $82.3M
- EPS (diluted)
- $-0.32
- Shares outstanding
- 125.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 8, 2021
Cognition Therapeutics Inc (CGTX) Stock Price
- Reported a net loss of $23.5M.
- Trading 71% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review COGNITION THERAPEUTICS INC.
Write a review
News about COGNITION THERAPEUTICS INC
News & sentiment via Polygon.io
Cognition Therapeutics Inc: frequently asked questions
Is Cognition Therapeutics Inc an American company?
Cognition Therapeutics Inc is a US-based company headquartered in Purchase, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Cognition Therapeutics Inc headquartered?
Cognition Therapeutics Inc is headquartered in Purchase, New York, United States.
Is Cognition Therapeutics Inc publicly traded?
Yes — Cognition Therapeutics Inc is a publicly traded company. Its stock trades under the ticker symbol CGTX on the NASDAQ.
What does Cognition Therapeutics Inc do?
Cognition Therapeutics Inc is an American Pharmaceuticals company in the Health & Beauty sector.
